Actively Recruiting
PET/MRI to Stage Prostate Cancer Patients
Led by IRCCS San Raffaele · Updated on 2024-07-03
50
Participants Needed
1
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main goal of this phase II clinical trial is to define a novel approach of staging prostate cancer (PCa) patients by using a fully integrated positron emission tomography/ magnetic resonance imaging (PET/MRI) system with 68Ga-prostate specifica membrane antigen (PSMA) and 68Ga-RM2 (bombesin antagonist). 50 patients with biopsy proven PCa will be studied by PET/MRI with 68Ga-PSMA and with 68Ga-RM2 and then will undergo prostatectomy and pelvic lymphadenectomy.
CONDITIONS
Official Title
PET/MRI to Stage Prostate Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Biopsy proven high-grade prostate cancer
- Scheduled for prostatectomy and pelvic or retroperitoneal lymphadenectomy
- Willing to provide signed informed consent
You will not qualify if you...
- Under 18 years old
- Unable to complete imaging exams (e.g., severe claustrophobia)
- Any medical condition interfering with study participation
- Contraindications for MRI (e.g., pacemaker)
- Evidence of metastatic disease on conventional imaging that prevents surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Ospedale San Raffaele
Milan, Italy, 20132
Actively Recruiting
Research Team
M
Maria Picchio, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here